On April 8, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported financial results for the fiscal quarter ended February 28, 2026, and highlighted continued execution across its registrational program for bexobrutideg, advancement of its broader pipeline, and multiple anticipated clinical and scientific catalysts in 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Nurix entered 2026 focused on implementing a comprehensive registrational program designed to establish bexobrutideg as a potential best-in-class medicine for patients with chronic lymphocytic leukemia," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "Building on compelling clinical data in oncology, we are also completing a series of healthy volunteer studies to support bexobrutideg’s development in selected immunology and inflammation indications where removal of the BTK protein through targeted protein degradation could offer advantages over BTK inhibitor drugs. Together with the advancement of our partnered degraders of STAT6 with Sanofi and IRAK-4 with Gilead, Nurix’s pipeline includes some of the most exciting new targets in the industry with the potential to address a wide spectrum of autoimmune diseases."

Program Highlights*

Bexobrutideg
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of BTK for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases.

DAYBreak CLL-201
Enrollment is ongoing in the DAYBreak CLL-201 pivotal Phase 2 single-arm study (NCT07221500) in patients with r/r CLL, which is designed to support a potential Accelerated Approval submission. The study is enrolling patients whose disease has progressed following treatment with a cBTKi, a BCL-2i, and an ncBTKi inhibitor, representing a population with significant unmet medical need. More information on the Phase 2 trial is available at www.clinicaltrials.gov.
DAYBreak CLL-306
Nurix plans to initiate a global randomized confirmatory Phase 3 trial by midyear 2026 to support full approval. The Phase 3 study will compare once daily bexobrutideg monotherapy to the most recently approved non-covalent inhibitor, pirtobrutinib, in patients with r/r CLL whose disease has progressed after prior BTK inhibitor therapy.
NX-5948-301
Nurix continues to enroll select cohorts in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed or refractory B cell malignancies. The Phase 1b study includes cohorts testing the safety and efficacy of the 600 mg dose of bexobrutideg in earlier lines of therapy in CLL patients. Updated data from this study are anticipated to be presented at upcoming medical meetings throughout 2026. More information on the ongoing Phase 1a/1b trial of bexobrutideg is available at www.clinicaltrials.gov.
Healthy volunteer SAD/MAD study
Nurix is conducting a Phase 1 single ascending and multiple ascending dose (SAD/MAD) study (NCT06717269) to evaluate pharmacokinetics (PK), pharmacodynamics (PD), and safety of a new tablet formulation of bexobrutideg. This study is intended to support an IND filing and enable expansion into immunology and inflammation indications in 2026. More information on the Phase 1 SAD/MAD trial of bexobrutideg is available at www.clinicaltrials.gov.
Zelebrudomide
Zelebrudomide is an orally bioavailable degrader of BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) designed for the treatment of relapsed or refractory B-cell malignancies. Nurix is conducting a Phase 1a/1b clinical trial (NCT04830137), including a Phase 1b expansion cohort focused on patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Nurix is enrolling in the dose escalation cohort of the Phase 1a/1b trial using the chirally controlled drug product. Additional information on the zelebrudomide clinical trial can be accessed at www.clinicaltrials.gov.

NX-1607
NX-1607 is an investigational oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) being developed for immuno-oncology indications, including a range of solid tumor types and lymphomas. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial (NCT05107674) in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. Additional information on the NX-1607 clinical trial can be accessed at www.clinicaltrials.gov.

Strategic collaborations with Gilead, Sanofi and Pfizer
Sanofi continues to advance the STAT6 degrader, NX-3911, in IND-enabling studies. Nurix retains the right to opt-in after clinical proof of concept to a 50/50 U.S. profit share and co-development agreement. Gilead continues to advance the IRAK4 degrader, GS-6791, in an ongoing first-in-human Phase 1 study in healthy volunteers. Nurix retains the right to opt-in after Phase 1 to a 50/50 U.S. profit share and co-development, subject to certain restriction. Nurix anticipates the achievement of substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi, and Pfizer.

*Expected timing of events throughout this press release is based on calendar year quarters.

Fiscal First Quarter 2026 Financial Results

Revenue for the three months ended February 28, 2026, was $6.3 million compared with $18.5 million for the three months ended February 28, 2025. Revenue from the collaboration with Sanofi decreased as the initial research term for certain drug targets ended.

Research and development expenses for the three months ended February 28, 2026, were $84.1 million compared with $69.7 million for the three months ended February 28, 2025. The increase was primarily related to compensation and related personnel costs, clinical costs and contract manufacturing costs as Nurix continued to accelerate the enrollment of patients in the ongoing Phase 2 trial of bexobrutideg and enable the initiation of Phase 3 trials.

General and administrative expenses for the three months ended February 28, 2026, were $14.6 million compared with $11.7 million for the three months ended February 28, 2025. The increase was primarily due to an increase in compensation and related personnel costs.

Net loss for the three months ended February 28, 2026, was $87.2 million or ($0.79) per share compared with $56.4 million or ($0.67) per share for the three months ended February 28, 2025.

Cash, cash equivalents and marketable securities were $540.7 million as of February 28, 2026, compared to $592.9 million as of November 30, 2025.

(Press release, Nurix Therapeutics, APR 8, 2026, View Source [SID1234664240])

On April 8, 2026 Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, reported that it has raised $5 million in additional funds for its Series B financing from new investor Hatteras Venture Partners. As part of the financing, Hatteras partner Kseniya Simpson, Ph.D., will join the Company’s board of directors and Hatteras general partner Christy Shaffer, Ph.D., will join as a board observer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by Hatteras’s strong enthusiasm for our CDK2 program and their support in advancing INX-315 toward meaningful clinical outcomes," said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio. "Additionally, we’re pleased to welcome Kseniya and Christy to our board and look forward to working with them during this pivotal time of growth for Incyclix."

The additional funds will support of the clinical development of the Company’s lead compound INX-315, a novel, potent and selective CDK2 inhibitor, for the treatment of advanced and metastatic breast and ovarian cancer. Hatteras joins other top-tier investors who participated in the Series B round, including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital.

"CDK2 inhibition represents an exciting opportunity to address unmet need that remains in breast and ovarian cancer treatment," said Kseniya Simpson, Ph.D. "We believe in Incyclix’s highly experienced team and their capabilities to bring a best-in-class treatment option to patients with advanced and resistant cancer."

The Phase 1/2 open-label, dose-escalation, combination and dose-expansion clinical trial of INX-315 is ongoing. More information on the INX-315-10 trial can be found at clinicaltrials.gov (NCT05735080).

(Press release, Incyclix Bio, APR 8, 2026, View Source [SID1234664257])

On April 8, 2026 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, reported the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

25th Annual Needham Virtual Healthcare Conference
Format: Virtual Corporate presentation
Date/Time: Tuesday, April 14, 2026 at 9:30am ET
Webcast Link: Precision BioSciences Virtual Presentation Link

If you are interested in meeting with the Precision team during the conference, please reach out to your Needham representative.

A replay of the presentation will be available on the Company’s website in the Investors section under Events and Presentations following the event.

(Press release, Precision Biosciences, APR 8, 2026, View Source [SID1234664241])

On April 8, 2026 Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, reported that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 130mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors1. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides recommendations regarding trial continuation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the rapid progress of the Phase 1 ‘HEAT’ trial of RAD202, as it underscores the favorable safety profile, allowing us to accelerate the dose escalation from Cohort 2 to Cohort 3." said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "Considering the current progress and the strong execution, we remain on track to complete the Phase 1 dose escalation by the end of 2026."

The Phase 1 ‘HEAT’ study is currently being conducted at clinical centers across Australia. The announcement of the previous dose level in this study of 75mCi was released on 1 October 2025.

About 177Lu-RAD202:

RAD202 is a proprietary single-domain monoclonal antibody (sdAb) that targets the Human Epidermal Growth Factor Receptor 2 (HER2)-positive expression in advanced solid tumors. HER2 is overexpressed in breast cancer and several other solid tumors and represents a validated target in oncology. In a previous diagnostic study of ten HER2-positive breast cancer patients, RAD202 demonstrated clinical proof-of-concept and had positive safety and biodistribution.

(Press release, Radiopharm Theranostics, APR 8, 2026, View Source [SID1234664258])

On April 8, 2026 Trogenix Ltd ("Trogenix"), a pioneering biotech company dedicated to developing innovative cancer therapies reported the publication of its breakthrough pre-clinical data in Nature reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM). The research supports an innovative approach to potentially achieving curative responses with long-term immunological protection against GBM, the most lethal form of brain cancer. It underpins the Company’s transition to a clinical-stage oncology company, with patient dosing in its first clinical trial for glioblastoma expected in Q2 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, authored by scientists from the University of Edinburgh, UCL Cancer Institute and The Royal Infirmary of Edinburgh, focusses on Trogenix’s proprietary Synthetic Super-Enhancers (SSEs), which are engineered genetic constructs that act as selective transcriptional switches, designed to harness glioblastoma stem cells’ own unique transcriptional machinery. The SSEs, delivered using adeno-associated virus vectors (AAVs), specifically target SOX2 and SOX9-driven gene networks that are activated in patient glioblastoma stem cells. Key findings of the study showed that, when delivered as a single treatment dose, SSEs led to:

Striking tumour regression within 1-2 weeks, and complete tumour clearance in 83% of treated cases over the subsequent 2-3 weeks
Precision immune activation to eradicate tumours
No further tumour regrowth after the initial treatment, with no toxicity over the next 11 months
No detectable tumour formation even after re-challenge
Critically, SSE activity was validated using fresh patient GBM tissue samples, demonstrating selective expression in tumour cells but not in the healthy normal brain cells. This precision targeting of glioblastoma cells while sparing normal tissue minimises off-target toxicities and represents a key validation step before advancing to patient trials.

Professor Steve Pollard, Study Lead at the University of Edinburgh and Chief Scientific Officer of Trogenix, said: "This pre-clinical work in an aggressive brain cancer model that closely mimics human glioblastoma has achieved what we thought impossible – complete tumour elimination and long-lasting protection against cancer recurrence without off-target toxicity using a single dose of a single agent. Our Synthetic Super-Enhancer technology combines the dual power of cancer cell killing and immune stimulation through a sophisticated ‘Trojan horse’ precision delivery method with the potential for transforming how we address GBM. We can finally hit the tumour hard and early by using controlled gene therapy that has been designed to be highly selective for the most aggressive cancer cells. We are committed to move these findings as quickly and safely as possible to patients and are optimistic that this can provide a new approach to tackling solid tumours. We look forward to starting our Phase I/II ADePT trial for glioblastoma this year."

The dual-payload approach delivers two therapeutic agents directly to cancer cells: HSV-TK for direct tumour killing (cytotoxic) and IL-12 for immune system activation (cytokine), creating synergistic effects that act as an in-situ vaccine. This approach generates durable immunological memory that prevents cancer recurrence by educating the immune system to detect cancer, transforming gene therapy from temporary intervention to lasting protection.

Dr Iain Foulkes, Chief Executive of Cancer Research Horizons, said: "Around 3,200 people are diagnosed with glioblastoma every year in the UK, of which just 160 will survive for five years or more. That number is unacceptable and we urgently need better treatment options. This work lays the foundation for Trogenix’s next steps into early-stage clinical trials, steps that will hopefully take us closer to a world where fewer people lose their lives to brain cancer. Cancer Research Horizons remains committed to supporting Trogenix’s mission to target aggressive cancers, and we’re excited to see if their promising precision science can benefit patients."

This work was funded by Cancer Research UK and the Biotechnology and Biological Sciences Research Council (BBSRC). Trogenix spun out of the University of Edinburgh in 2024, co-founded by Professor Steve Pollard, based on a decade of research.

(Press release, Trogenix, APR 8, 2026, View Source;utm_medium=rss&utm_campaign=trogenix-announces-publication-of-breakthrough-pre-clinical-data-in-nature-demonstrating-complete-tumour-eradication-and-durable-protection-in-aggressive-brain-cancer-model [SID1234664242])